{"id":7124,"date":"2020-10-18T16:38:33","date_gmt":"2020-10-18T13:38:33","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=7124"},"modified":"2025-04-20T17:17:11","modified_gmt":"2025-04-20T14:17:11","slug":"favipiravir-nedir-favipiravir-yan-etkileri-nelerdir","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=7124","title":{"rendered":"Favipiravir Nedir? Favipiravir Yan Etkileri Nelerdir?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">\u015euan d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndan bildirilen 16 milyondan fazla vaka var ve giderek artmakta.  <strong>Sadece 125 mikron \u00e7ap\u0131nda<\/strong> olan SARS-CoV-2, d\u00fcnyam\u0131z \u00fczerinde <strong>silinmez bir etki b\u0131rakt\u0131<\/strong>. Bu hastal\u0131kla sava\u015fmak i\u00e7in yeni ila\u00e7lar\u0131n yetersizli\u011fi ile t\u0131p bilimi, bu yeni koronavir\u00fcse kar\u015f\u0131 etkili olabilecek, yeniden ama\u00e7land\u0131r\u0131lm\u0131\u015f ila\u00e7lar\u0131 belirleme yar\u0131\u015f\u0131nda. Ba\u015flang\u0131\u00e7ta <strong>influenza<\/strong> i\u00e7in tasarlanm\u0131\u015f, <strong>favipiravir<\/strong> ad\u0131 verilen anti-viral bir ara\u015ft\u0131rmalarda \u00f6n plana \u00e7\u0131k\u0131yor. Bu makalede, COVID-19 tedavisinde rol\u00fcn\u00fc a\u00e7\u0131kl\u0131\u011fa kavu\u015fturmak i\u00e7in mevcut pandemi ba\u011flam\u0131nda bu ilac\u0131n kapsaml\u0131, kan\u0131ta dayal\u0131 bir incelemesini sunmaya \u00e7al\u0131\u015ft\u0131m.<\/p>\n\n\n\n<figure class=\"wp-block-embed-youtube wp-block-embed is-type-video is-provider-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"video-shortcode\"><iframe title=\"Favipiravir&#039;in Cryo-EM yap\u0131s\u0131, katalitik durumda SARS-CoV-2&#039;nin replike edici polimeraz kompleksi\" width=\"1200\" height=\"675\" src=\"https:\/\/www.youtube.com\/embed\/DZXCZgW8HsI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><figcaption>Favipiravir Covid-19&#8217;un Protein Yap\u0131s\u0131na Ba\u011flan\u0131yor. <br>PDB: <a href=\"https:\/\/www.rcsb.org\/structure\/7CTT\">7CTT<\/a><br><strong>DOI:&nbsp;<\/strong><a href=\"http:\/\/doi.org\/10.2210\/pdb7CTT\/pdb\" target=\"_blank\" rel=\"noreferrer noopener\">10.2210\/pdb7CTT\/pdb<\/a><\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Aral\u0131k 2019&#8217;dan beri COVID-19 d\u00fcnyan\u0131n hemen her k\u00f6\u015fesine yay\u0131ld\u0131. Teorik olarak, tocilizumab ve <strong>favipiravir<\/strong>, COVID-19&#8217;un y\u00fcksek IL-6 ile tedavisi i\u00e7in g\u00fcvenilir ila\u00e7lar olarak kabul edilir(Kaynak: <a href=\"https:\/\/0210l2qx8-y-https-doi-org.proxy.elibrary.atauni.edu.tr\/10.1016\/j.biopha.2020.110825\">Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size<\/a>). Favipiravir T\u00fcrkiye&#8217;de Favicovir ad\u0131 ile de kullan\u0131lmaktad\u0131r. Favicovir ile ilgili ayr\u0131nt\u0131l\u0131 bilgi i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=6628\">Favicovir Yan Etkileri ve Ayr\u0131nt\u0131l\u0131 \u0130nceleme<\/a> adl\u0131 yaz\u0131y\u0131 okuyabilirsiniz.<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<!-- Yatay_G\u00f6rnt\u00fcl\u00fc -->\n<ins class=\"adsbygoogle\" style=\"display:block\" data-ad-client=\"ca-pub-7050495227290123\" data-ad-slot=\"6780495801\" data-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<h2 class=\"wp-block-heading\">Favipiravir Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">2019&#8217;un sonunda, Wuhan \u00c7in&#8217;de birka\u00e7 a\u00e7\u0131klanamayan viral pn\u00f6moni ortaya \u00e7\u0131kt\u0131 ve ard\u0131ndan h\u0131zla d\u00fcnya yay\u0131ld\u0131 [<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMOa2001316\">1<\/a>]. 28 May\u0131s 2020 itibariyle, d\u00fcnya \u00e7ap\u0131nda 5,7 milyondan fazla ki\u015fi enfekte olmu\u015f ve 350000&#8217;den fazla ki\u015fi hayat\u0131n\u0131 kaybetmi\u015ftir [<a href=\"http:\/\/2019ncov.chinacdc.cn\/2019-nCoV\/global.html\">2<\/a>].<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eiddetli akut solunum sendromu koronavir\u00fcs 2 (SARS-CoV-2) salg\u0131n\u0131 k\u00fcresel olarak yay\u0131l\u0131yor. Bununla birlikte, klinik olarak etkili <strong>antiviral tedaviler<\/strong> olu\u015fturulmam\u0131\u015ft\u0131r. <strong>Favipiravir<\/strong>, pn\u00f6moni ve akut solunum s\u0131k\u0131nt\u0131s\u0131 sendromunun \u015fiddetlenmesini \u00f6nleyebilir(Kaynak: <a href=\"https:\/\/0210l2qx8-y-https-doi-org.proxy.elibrary.atauni.edu.tr\/10.1016\/j.ijid.2020.08.047\">Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition<\/a>).<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<!-- Yatay_G\u00f6rnt\u00fcl\u00fc -->\n<ins class=\"adsbygoogle\" style=\"display:block\" data-ad-client=\"ca-pub-7050495227290123\" data-ad-slot=\"6780495801\" data-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 i\u00e7in etkili <strong>antiviral tedaviler<\/strong> yeterince olu\u015fturulmam\u0131\u015ft\u0131r ve <strong>SARS-CoV-2<\/strong> i\u00e7in <strong>antiviral tedaviye ili\u015fkin bilgiler s\u0131n\u0131rl\u0131d\u0131r<\/strong>. RNA vir\u00fcslerinin <strong><a href=\"https:\/\/www.ortaakarsu.net\/?p=6446\">RNA polimeraz\u0131n\u0131 inhibe<\/a> ederek influenzay\u0131 tedavi etmek<\/strong> i\u00e7in geli\u015ftirilen <strong>Favipiravir<\/strong>, SARS-CoV-2&#8217;ye kar\u015f\u0131 etkili olabilir (Furuta ve di\u011ferleri, 2013, Shiraki ve Daikoku, 2020). \u00d6rne\u011fin, <strong>favipiravir<\/strong>&#8216;in bir klinik denemesi, <strong>t\u00fcm hastalarda ate\u015f ve \u00f6ks\u00fcr\u00fckte azalma ve orta \u015fiddette hastalarda iyile\u015fme<\/strong> oran\u0131n\u0131n artt\u0131\u011f\u0131n\u0131 bildirmi\u015ftir; ancak \u015fiddetli veya kritik durumdaki hastalar aras\u0131ndaki iyile\u015fme oran\u0131 de\u011fi\u015fmeden kalm\u0131\u015ft\u0131r (Chen ve di\u011ferleri, 2020a).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Favipiravir Yan Etkileri \/ Ters Etkileri<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Daha \u00f6nce tart\u0131\u015f\u0131lan <a href=\"http:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_casereport_en_200529.pdf\">Japon \u00e7al\u0131\u015fmas\u0131<\/a>, favipiravir alan hastalar\u0131n yakla\u015f\u0131k %20&#8217;sinde (COVID-19 i\u00e7in onaylanandan daha d\u00fc\u015f\u00fck bir dozda) advers reaksiyonlar\u0131n g\u00f6r\u00fcld\u00fc\u011f\u00fcn\u00fc bulmu\u015ftur. <strong>Yan etkiler nispeten k\u00fc\u00e7\u00fckt\u00fc<\/strong> ve <strong>kat\u0131l\u0131mc\u0131lar\u0131n %5&#8217;inde hiper\u00fcrisemi ve ishal<\/strong> durumu olu\u015ftu. Kat\u0131l\u0131mc\u0131lar\u0131n <strong>%2&#8217;sinde n\u00f6trofil say\u0131s\u0131 ve transaminiti azald\u0131<\/strong>. Bir \u00e7al\u0131\u015fma, <strong>favipiravir ile ili\u015fkili olarak psikiyatrik semptomlar\u0131n ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir<\/strong>. <strong>Favipiravirin QTc uzamas\u0131ndaki etkisi hala belirsizdir<\/strong>, baz\u0131 farmakodinamik \u00e7al\u0131\u015fmalar pozitif bir ili\u015fki oldu\u011funu d\u00fc\u015f\u00fcnd\u00fcrmektedir, ancak Japon \u00e7al\u0131\u015fmas\u0131 aksini \u00f6nermektedir(DOI:&nbsp;<a href=\"https:\/\/doi.org\/10.5414\/cp202388\" target=\"_blank\" rel=\"noreferrer noopener\">10.5414\/cp202388<\/a>&nbsp;). Genel olarak,<strong> favipiravir<\/strong>, b\u00fcy\u00fck bir sistematik inceleme ile teyit edildi\u011fi \u00fczere<strong> iyi bir g\u00fcvenlilik profiline sahiptir<\/strong>. <strong>Favipiravir Yan Etkileri \u015fu \u015fekilde s\u0131ralanabilir:<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Hiper\u00fcrisemi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir kullan\u0131m\u0131, hiper\u00fcrisemi prevalans\u0131nda doza ba\u011fl\u0131 bir art\u0131\u015f e\u011filimi ile sonu\u00e7lan\u0131r<\/strong>(<a href=\"https:\/\/www.pmda.go.jp\/files\/000210319.pdf\">Kaynak<\/a>). <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7213073\/\">Pilkington ve arkada\u015flar\u0131<\/a> taraf\u0131ndan y\u00fcr\u00fct\u00fclen sistematik bir inceleme, birden fazla \u00e7al\u0131\u015fmada benzer e\u011filimler bulmu\u015ftur. Ancak bu, klinik belirtilerle ili\u015fkili de\u011fildir. <strong>Favipiravir<\/strong>&#8216;in neden oldu\u011fu <strong>hiper\u00fcriseminin klinik belirtilere yol a\u00e7t\u0131\u011f\u0131na dair hi\u00e7bir kan\u0131t yoktur; ancak, bu riski tam olarak de\u011ferlendirmek i\u00e7in daha uzun takip d\u00f6nemleri gerekecektir.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Teratojenite<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir&#8217;in teratojenik potansiyele ve embriyotoksisiteye sahip oldu\u011funa dair kan\u0131t vard\u0131r.<\/strong> Japon ila\u00e7 g\u00fcvenlik b\u00fcrosu onay\u0131, <strong>favipiravir&#8217;e \u00fcreme \u00e7a\u011f\u0131ndaki kad\u0131nlarda kullan\u0131ma kar\u015f\u0131 g\u00fc\u00e7l\u00fc bir uyar\u0131 verilmesini tavsiye etmekte, ambalaj ve re\u00e7ete uyar\u0131lar\u0131 hakk\u0131nda ihtiyati ifadeler \u00f6nermektedir<\/strong>. B\u00fcro ayr\u0131ca, <strong>alternatif ila\u00e7lar\u0131n kullan\u0131labilece\u011fi durumlarda favipiravir&#8217;den ka\u00e7\u0131n\u0131lmas\u0131n\u0131 \u00f6nermektedir<\/strong>(<a href=\"https:\/\/www.pmda.go.jp\/files\/000210319.pdf\">Kaynak<\/a>). <strong>Favipiravir \u00e7ocuk do\u011furma \u00e7a\u011f\u0131ndaki kad\u0131nlara re\u00e7ete edilmeden \u00f6nce, negatif idrar gebelik testi ile gebeli\u011fin ekarte edilmesi zorunludur. <\/strong><a href=\"https:\/\/www.ortaakarsu.net\/?p=6628\">Favicovir Yan Etkileri ve Favicovir Kullananlar<\/a> adl\u0131 yaz\u0131da da inceleme yapabilirsiniz.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Favipiravir ile Tedavi<\/h2>\n\n\n\n<figure class=\"wp-block-embed-youtube wp-block-embed is-type-video is-provider-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"video-shortcode\"><iframe title=\"Antiviral drugs for the flu | Infectious diseases | Health &amp; Medicine | Khan Academy\" width=\"1200\" height=\"675\" src=\"https:\/\/www.youtube.com\/embed\/NaZTlnDlnOA?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><figcaption>Antiviral \u0130la\u00e7lar Nas\u0131l \u00c7al\u0131\u015f\u0131r? <\/figcaption><\/figure>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<!-- Yatay_G\u00f6rnt\u00fcl\u00fc -->\n<ins class=\"adsbygoogle\" style=\"display:block\" data-ad-client=\"ca-pub-7050495227290123\" data-ad-slot=\"6780495801\" data-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir<\/strong> bir antiviral olarak videoda anlat\u0131lan antivirallerin mekanizmalar\u0131na benzer \u015fekilde etki eder. Bir vir\u00fcs canl\u0131ya bula\u015ft\u0131\u011f\u0131nda vir\u00fcs\u00fcn yol a\u00e7t\u0131\u011f\u0131 hastal\u0131\u011f\u0131n tedavisi birden fazla \u015fekilde olabilmektedir. <strong>Favicovir<\/strong> ile ilgili olan yaz\u0131da bundan daha ayr\u0131nt\u0131l\u0131 bahsedilmi\u015ftir. Covid19 i\u00e7in resmi olarak onaylanan ilk ise <a href=\"https:\/\/www.ortaakarsu.net\/?p=7148\">Remdesivir, Covid-19 i\u00e7in Umut Vadeden \u0130la\u00e7<\/a> adl\u0131 yaz\u0131da g\u00f6rece\u011finiz gibi <strong>remdesivir&#8217;dir<\/strong>. Zaman ge\u00e7tik\u00e7e daha fazla ilac\u0131n bu konuda resmi onay almas\u0131 beklenebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">K\u0131\u015f mevsiminin bu yaz\u0131 yaz\u0131ld\u0131\u011f\u0131 s\u0131ralarda gelmesi ile birlikte, <strong>COVID-19<\/strong> i\u00e7in bir a\u015f\u0131n\u0131n kitlesel boyutta <strong>uygulamaya hala ge\u00e7ilmemi\u015f<\/strong> olmas\u0131 salg\u0131nda yeni bir dalga endi\u015felerini do\u011furmu\u015ftur. Art\u0131k mesele havalar\u0131n so\u011fumas\u0131 ile birlikte so\u011fuk alg\u0131nl\u0131 ve grip gibi hastal\u0131klar\u0131n koronavir\u00fcs hastal\u0131\u011f\u0131ndan do\u011fru \u015fekilde ay\u0131rt edilmesidir. Bunun i\u00e7in de grip vir\u00fcslerine kar\u015f\u0131 geli\u015ftirilen a\u015f\u0131lar\u0131n yap\u0131larak grip vakalar\u0131n\u0131n en aza indirilmesi ama\u00e7lanm\u0131lt\u0131r. T\u00fcrkiye Cumhuriyeti Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 bu \u00e7er\u00e7evede grip a\u015f\u0131s\u0131 uygulamas\u0131na ge\u00e7mi\u015ftir. \u00d6zellikle risk grubundaki ki\u015filerin grip yani infuluenza a\u015f\u0131s\u0131 yapt\u0131rmas\u0131 covid vakalar\u0131n\u0131n ay\u0131rt edilmesi ve erkenden tedaviye ba\u015flanabilmesi a\u00e7\u0131s\u0131ndan \u00e7ok \u00f6nemlidir. Grip a\u015f\u0131s\u0131 ile ilgili daha fazla bilgi i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=7176\">\u0130nfluenza A\u015f\u0131s\u0131 ve A\u015f\u0131 Olman\u0131n \u00d6nemi<\/a> adl\u0131 yaz\u0131y\u0131 okuman\u0131z faydali olacakt\u0131r. Covid-19 tedavisinde kullan\u0131lan bir di\u011fer ila\u00e7 olan <strong>Plaquenil yan etkilerini<\/strong> \u00f6\u011frenmek i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=7196\">Plaquenil Yan Etkileri Nelerdir?<\/a> adl\u0131 yaz\u0131y\u0131 okuyabilirsiniz.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Akademik \u00c7al\u0131\u015fmalardan Elde Edilen Veriler<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Akademik bir \u00e7al\u0131\u015fmada, COVID-19 hastalar\u0131n\u0131 <strong>favipiravir<\/strong> ile tedavi s\u00fcreci ger\u00e7ekle\u015fti. Kritik durumda olan iki hasta, nazal y\u00fcksek ak\u0131\u015f veya ECMO kurtarma tedavisi yoluyla% 100 oksijene ihtiya\u00e7 duydu ve \u015fiddetli bir durumda olan bir hasta, 8 L \/ dak maksimum oksijen al\u0131m\u0131na ihtiya\u00e7 duydu. K\u00f6t\u00fcle\u015fen ko\u015fullar nedeniyle semptomlar\u0131n ba\u015flamas\u0131ndan sonra t\u00fcm hastalar <strong>11. g\u00fcnde favipiravir uygulamas\u0131na ba\u015flam\u0131\u015ft\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SARS-CoV-2 semptom ba\u015flang\u0131c\u0131ndan 10 g\u00fcn sonra <\/strong>\u00e7o\u011fal\u0131r (Zou ve di\u011ferleri, 2020) ve <strong>sitokin f\u0131rt\u0131nalar\u0131<\/strong> veya ARDS tipik olarak semptom ba\u015flang\u0131c\u0131ndan <strong>8-14 g\u00fcn sonra ba\u015flar<\/strong> (Huang ve di\u011ferleri, 2020). SARS-CoV-2 viremia bu durumlar\u0131 ind\u00fckleyebilir (Chen ve di\u011ferleri, 2020b). <strong>ARDS, yakla\u015f\u0131k %74&#8217;l\u00fck bir \u00f6l\u00fcm oran\u0131yla daha y\u00fcksek bir \u00f6l\u00fcm riskine yol a\u00e7ar <\/strong>(Yang ve di\u011ferleri, 2020). F<strong>avipiravir<\/strong>, SARS-CoV-2 proliferasyonunu potansiyel olarak inhibe eder (Furuta ve di\u011ferleri, 2013, Shiraki ve Daikoku, 2020), bu da sitokin \u00fcretiminin azalmas\u0131na neden olabilir ve akci\u011feri sonraki hipoksemide fibrozdan koruyabilir (Yamamura ve di\u011ferleri, 2020). \u015eiddetli olmayan hastalar aras\u0131nda durum ayn\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Yak\u0131n zamanda yap\u0131lan bir favipiravir \u00e7al\u0131\u015fmas\u0131, daha erken bir viral klirens zaman\u0131 g\u00f6sterdi<\/strong> (4&#8217;e kar\u015f\u0131 11 g\u00fcnl\u00fck medyan) (Cai ve di\u011ferleri, 2020). Bununla birlikte, hastalar\u0131m\u0131z s\u0131ras\u0131yla 18, 27 ve 13 g\u00fcnlerde viral klirense sahipti, bu muhtemelen semptomlar\u0131n k\u00f6t\u00fcle\u015fmesinin ortas\u0131nda daha y\u00fcksek viral replikasyonu yans\u0131t\u0131yordu (Liu ve di\u011ferleri, 2020).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Favipiravir&#8217;in Etkisi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ek olarak, \u00e7al\u0131\u015fma <strong>favipiravir ile tedavi edilen hastalarda g\u00f6\u011f\u00fcs g\u00f6r\u00fcnt\u00fclemede iyile\u015fme g\u00f6sterdi<\/strong>. <strong>Favipiravir<\/strong>, y\u00fcksek viral y\u00fcke sahip \u015fiddetli vakalarda bile etkili bir \u015fekilde \u00e7al\u0131\u015fabilir (Takahashi ve di\u011ferleri, 2003).<strong> Favipiravir<\/strong>&#8216;in <strong>SARS-CoV-2 vir\u00fcs replikasyonunu inhibe etti\u011fi ba\u015fl\u0131ca mekanizmalar, RNA sentezine ve \u00f6l\u00fcmc\u00fcl mutageneze kar\u015f\u0131 \u00f6nemli inhibe edici aktivitesidir <\/strong>(Shannon ve di\u011ferleri, 2020)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00dc\u00e7 COVID-19 vakas\u0131yla ilgili b\u00f6l\u00fcm\u00fcn sonunda kayna\u011f\u0131 belirtilen makalede, <strong>favipiravir<\/strong>&#8216;in pn\u00f6moni ilerlemesini ve sitokin art\u0131\u015f\u0131n\u0131 yava\u015flatabilece\u011fi \/ durdurabilece\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Ayr\u0131ca solunum fonksiyonunu iyile\u015ftirebilece\u011fini ve \u015fiddetli veya kritik durumdaki hastalarda bile ani etkiler olu\u015fturabilece\u011fini g\u00f6r\u00fclm\u00fc\u015ft\u00fcr. Bununla birlikte, yine kayna\u011f\u0131 a\u015fa\u011f\u0131da belirtilen makalede g\u00f6zlemler,<strong> favipiravir<\/strong>&#8216;in \u015fiddetli veya kritik hastalar\u0131n tedavisinde d\u00fc\u015f\u00fcn\u00fclebilece\u011fini g\u00f6stermektedir.<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<!-- Yatay_G\u00f6rnt\u00fcl\u00fc -->\n<ins class=\"adsbygoogle\" style=\"display:block\" data-ad-client=\"ca-pub-7050495227290123\" data-ad-slot=\"6780495801\" data-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p class=\"wp-block-paragraph\">Bu b\u00f6l\u00fcm i\u00e7in kaynak ve daha ayr\u0131nt\u0131l\u0131 bilgi i\u00e7in:<a href=\"https:\/\/0210l2qx8-y-https-doi-org.proxy.elibrary.atauni.edu.tr\/10.1016\/j.ijid.2020.08.047\"> Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition<\/a> ziyaret edebilirsiniz. Kaynak makalede \u00f6rnek vaka incelemeleri ile favipiravir kullan\u0131m\u0131n\u0131n bu vakalar \u00fczerindeki etkisi incelenmi\u015ftir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">D\u00fcnyada Kullan\u0131m\u0131 ve Farmakoloji<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir ilk olarak pandeminin tam merkez \u00fcss\u00fcnde Wuhan&#8217;da SARS-CoV-2&#8217;ye kar\u015f\u0131 kullan\u0131ld\u0131<\/strong>. Daha sonra, pandemi Avrupa&#8217;ya yay\u0131ld\u0131. Avrupa&#8217;ya yay\u0131las\u0131 ile ila\u00e7 \u0130talya&#8217;da acil kullan\u0131m i\u00e7in onay ald\u0131. Sonras\u0131nda \u015fu anda Japonya, Rusya, Ukrayna, \u00d6zbekistan, Moldova ve Kazakistan&#8217;da kullan\u0131l\u0131yor. Yak\u0131n zamanda Suudi Arabistan ve BAE&#8217;de de onay verildi. Bundan sonra <a href=\"https:\/\/www.ortaakarsu.net\/?p=6628\"><strong>T\u00fcrkiye(Favicovir)<\/strong><\/a>, Banglade\u015f ve son olarak M\u0131s\u0131r da son zamanlarda ticari lansmanlara tan\u0131k oldu. Haziran 2020&#8217;de <strong>favipiravir<\/strong>, Hindistan&#8217;da hafif ve orta derecede COVID-19 enfeksiyonlar\u0131 i\u00e7in DCGI onay\u0131n\u0131 ald\u0131. 23 Temmuz 2020 itibar\u0131yla; COVID-19&#8217;un y\u00f6netiminde bu ilac\u0131n kullan\u0131m\u0131n\u0131 de\u011ferlendirmek i\u00e7in <a href=\"http:\/\/clinicaltrials.gov\/\">kliniktrials.gov<\/a>&#8216;da kay\u0131tl\u0131 32 \u00e7al\u0131\u015fma vard\u0131r.<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<!-- Yatay_G\u00f6rnt\u00fcl\u00fc -->\n<ins class=\"adsbygoogle\" style=\"display:block\" data-ad-client=\"ca-pub-7050495227290123\" data-ad-slot=\"6780495801\" data-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir<\/strong> ve di\u011fer ila\u00e7lar\u0131n nas\u0131l ke\u015ffedildi\u011fini \u00f6\u011frenmek i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=6671\">Koronavir\u00fcs \u0130la\u00e7 Geli\u015ftirme \u00c7al\u0131\u015fmalar\u0131<\/a> ve <a href=\"https:\/\/www.ortaakarsu.net\/?p=6403\">Bilgisayar Destekli \u0130la\u00e7 Tasar\u0131m\u0131 (CADD)<\/a> adl\u0131 yaz\u0131lar\u0131 okuyarak bilgi sahibi olabilirsiniz.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Kimyasal ve Farmakolojik Olarak Favipiravir<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir<\/strong> (T-705), ilk olarak Toyoma kimyasallar\u0131n\u0131n buldu\u011fu bir bile\u015fiktir. \u015eirketin kimyasal madde k\u00fct\u00fcphanesinde <strong>influenza vir\u00fcs\u00fcne kar\u015f\u0131 aktif kimyasal ajanlar\u0131n antiviral aktivitesini de\u011ferlendirirken ke\u015ffedilen sentetik bir \u00f6n ila\u00e7t\u0131r<\/strong>. Daha sonra T-1105 olarak adland\u0131r\u0131lan bir aktif bile\u015fik, A \/ PR \/ 8\/34 ve t\u00fcrevlerinin <strong>antiviral aktivitelere sahip oldu\u011fu bulundu<\/strong>. <strong>Favipiravir<\/strong>, T-1105&#8217;in pirazin k\u0131sm\u0131n\u0131n kimyasal modifikasyonu ile elde edilir. Japonya&#8217;da, 2014 y\u0131l\u0131nda ortaya \u00e7\u0131kan <strong>pandemik influenza enfeksiyonlar\u0131n\u0131n y\u00f6netimi i\u00e7in onaylanm\u0131\u015ft\u0131r<\/strong>.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"533\" height=\"192\" src=\"https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr1.jpg\" alt=\"Favipiravir t\u00fcrevleri. \u00c7e\u015fitlilik artarak etkileri denenmi\u015ftir.\" class=\"wp-image-7126\" srcset=\"https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr1-300x108.jpg 300w, https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr1-500x180.jpg 500w, https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr1.jpg 533w\" sizes=\"(max-width: 533px) 100vw, 533px\" \/><figcaption>Favipiravir&#8217;in t\u00fcrevleri. \u00c7e\u015fitlilik artt\u0131r\u0131larak etkileri de\u011ferlendirilmi\u015ftir. Kaynak: <a href=\"https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004\">Favipiravir: A new and emerging antiviral option in COVID-19<\/a><\/figcaption><\/figure><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Farmakokinetik ve Farmakodinamik \u00d6zellikler<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir bir \u00f6n ila\u00e7 olarak uygulan\u0131r<\/strong>. M\u00fckemmel bir <strong>biyoyararlan\u0131ma (\u223c% 94),% 54 proteine \u200b\u200bba\u011flanmaya ve d\u00fc\u015f\u00fck bir da\u011f\u0131l\u0131m hacmine (10-20 L) sahiptir<\/strong>. Tek dozdan 2 saat sonra Cmax&#8217;a ula\u015f\u0131r. Birden fazla dozdan sonra hem Tmax hem de yar\u0131lanma \u00f6mr\u00fc artar. <strong>Favipiravir, hidroksile formda h\u0131zl\u0131 renal eliminasyona yol a\u00e7an k\u0131sa bir yar\u0131lanma \u00f6mr\u00fcne (2.5-5 saat) sahiptir<\/strong>. Eliminasyona aldehit oksidaz arac\u0131l\u0131k eder ve marjinal olarak ksantin oksidaz arac\u0131l\u0131k eder. <strong>Favipiravir, hem doza ba\u011fl\u0131 hem de zamana ba\u011fl\u0131 farmakokinetik sergiler<\/strong>. Sitokrom P450 sistemi taraf\u0131ndan metabolize edilmez, ancak bile\u015fenlerinden birini (CYP2C8) inhibe eder. Bu nedenle, <strong>CYP2C8 sistemi taraf\u0131ndan metabolize edilen ila\u00e7larla birlikte uyguland\u0131\u011f\u0131nda dikkatli kullan\u0131lmas\u0131 gerekir<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Favipiravir Etki Mekanizmas\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Doku i\u00e7inde molek\u00fcl, bu ilac\u0131n aktif formu olan <strong>favipiravir-RTP<\/strong>&#8216;ye fosforibosilasyona u\u011frar. Antiviral etkisini a\u015fa\u011f\u0131daki mekanizmalarla g\u00f6sterir:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Bu molek\u00fcl, enzim taraf\u0131ndan bir purin n\u00fckleotidi olarak kar\u0131\u015ft\u0131r\u0131lan RNA&#8217;ya ba\u011f\u0131ml\u0131 RNA-polimeraz (RdRp) enzimi i\u00e7in bir substrat g\u00f6revi g\u00f6r\u00fcr. B\u00f6ylece aktivitesini inhibe ederek viral protein sentezinin sonland\u0131r\u0131lmas\u0131na yol a\u00e7ar.<\/li><\/ul>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"557\" height=\"283\" src=\"https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr2.jpg\" alt=\"Favipiravir etki mekanizmas\u0131\" class=\"wp-image-7128\" srcset=\"https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr2-300x152.jpg 300w, https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr2-500x254.jpg 500w, https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr2-550x279.jpg 550w, https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/1-s2.0-S0377123720301581-gr2.jpg 557w\" sizes=\"(max-width: 557px) 100vw, 557px\" \/><figcaption>Favipiravir Etki Mekanizmas\u0131 Kaynak: <a href=\"https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004\">Favipiravir: A new and emerging antiviral option in COVID-19<\/a><\/figcaption><\/figure><\/div>\n\n\n\n<ul class=\"wp-block-list\"><li>Viral RNA sarmal\u0131na dahil olur ve daha fazla geni\u015flemeyi \u00f6nler. Bu etki mekanizmas\u0131, \u00e7e\u015fitli RNA vir\u00fcsleri boyunca RdRp enziminin katalitik alan\u0131n\u0131n korunmas\u0131yla birlikte, bu ilac\u0131n geni\u015f aktivite spektrumunu a\u00e7\u0131klar.<\/li><li>Son zamanlarda favipiravirin influenza vir\u00fcs\u00fc enfeksiyonu s\u0131ras\u0131nda in vitro \u00f6l\u00fcmc\u00fcl mutajenez ind\u00fckledi\u011fi ve onu vir\u00fcsidal bir ila\u00e7 haline getirdi\u011fi g\u00f6sterilmi\u015ftir. SARS-CoV-2&#8217;ye kar\u015f\u0131 benzer bir aktivitenin g\u00f6sterilip g\u00f6sterilmedi\u011fi belirsizdir.<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bir antiretroviral ajan olan <a href=\"https:\/\/www.ortaakarsu.net\/?p=6606\">Raltegravir \u2013 \u0130ntegraz \u0130nhibit\u00f6rlerinin \u0130lki<\/a> adl\u0131 yaz\u0131da Raltegravir&#8217;in \u00f6zellikleri anlat\u0131lmaktad\u0131r. Ayr\u0131ca <a href=\"https:\/\/www.ortaakarsu.net\/?p=6805\">Testosteron ve Steroid Molek\u00fcller<\/a> adl\u0131 yaz\u0131da neden Covid-19 tedevisinde steroid yap\u0131daki ila\u00e7lar\u0131n kullan\u0131ld\u0131\u011f\u0131 anlat\u0131lmaktad\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Antiviral Aktivite Spektrumu<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Influenza<\/strong>&#8216;ya Kar\u015f\u0131 Favipiravir<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Favipiravir, mevsimsel A (H1N1), A (H3N2) ve influenza B su\u015flar\u0131 dahil olmak \u00fczere 53 tip influenza vir\u00fcs\u00fcn\u00fc inhibe eder; A (H1N1) pdm09 pandemik vir\u00fcs\u00fc; insanlardan izole edilmi\u015f olduk\u00e7a patojenik ku\u015f gribi vir\u00fcs\u00fc A (H5N1); Domuzdan izole edilen A (H1N1) ve A (H1N2); ve A (H2N2), A (H4N2) ve A (H7N2). Ayr\u0131ca, M2 ve NA inhibit\u00f6rleri dahil olmak \u00fczere, vir\u00fcs\u00fcn ilaca diren\u00e7li su\u015flar\u0131na kar\u015f\u0131 da aktiftir. Kaynak: <a href=\"https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004\">Favipiravir: A new and emerging antiviral option in COVID-19<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130la\u00e7 ke\u015fif \u00e7al\u0131\u015fmalar\u0131n\u0131n nas\u0131l ger\u00e7ekle\u015fti\u011fini \u00f6\u011frenmek i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=7039\">Antimalaryal \u0130la\u00e7lar \u2013 Yap\u0131 Bazl\u0131 \u0130la\u00e7 Tasar\u0131m\u0131<\/a> ve <a href=\"https:\/\/www.ortaakarsu.net\/?p=75\">Docking ve Kanser Tedavisinde Kullan\u0131m\u0131<\/a> adl\u0131 yaz\u0131lar\u0131n\u0131 okuman\u0131z makaleleri anlaman\u0131z i\u00e7in fayda sa\u011flayacakt\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Ebola Vir\u00fcs\u00fc&#8217;ne Kar\u015f\u0131 Favipiravir<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">2014&#8217;teki Ebola vir\u00fcs\u00fc salg\u0131n\u0131 s\u0131ras\u0131nda, favipiravir, WHO taraf\u0131ndan denemeler i\u00e7in k\u0131sa listeye al\u0131nan ila\u00e7lardan biriydi. Her ne kadar in vitro \u00e7al\u0131\u015fmalar, bu ila\u00e7 i\u00e7in cesaret verici sonu\u00e7lar g\u00f6sterse de, klinik \u00e7al\u0131\u015fmalarda sa\u011fkal\u0131m yarar\u0131na y\u00f6nelik bir e\u011filim g\u00f6sterilmi\u015f olsa da, fayda ile ilgili kesin kan\u0131t hi\u00e7bir zaman bulunamad\u0131. 126 Ebola hastas\u0131nda y\u00fcr\u00fct\u00fclen JIKI \u00e7ok merkezli \u00e7al\u0131\u015fmas\u0131nda10, favipiravirin ba\u015flang\u0131\u00e7 \u200b\u200by\u00fckleme dozu olan 6000 mg ve ard\u0131ndan 9 g\u00fcn 2400 mg \/ g\u00fcn, orta ila y\u00fcksek viremili hastalarda bir miktar etkiye sahip oldu\u011fu ancak daha \u015fiddetli olanlarda etkisi olmad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. viremia (Ct de\u011feri &lt;20). Bu b\u00fcy\u00fck dozun da iyi tolere edildi\u011fi g\u00f6r\u00fcld\u00fc. Daha sonraki bir geriye d\u00f6n\u00fck \u00e7al\u0131\u015fma da, favipiravir ile tedavi edilen hastalar\u0131n Ebola vir\u00fcs\u00fcne kar\u015f\u0131 daha iyi hayatta kalma s\u00fcrelerine do\u011fru bir e\u011filim g\u00f6sterdiklerini bulmu\u015ftur. Ancak bu etki istatistiksel olarak anlaml\u0131 de\u011fildir. Kaynak: <a href=\"https:\/\/doi.org\/10.1016\/j.antiviral.2014.02.014\">1<\/a>,<a href=\"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.012\">2<\/a>,<a href=\"https:\/\/doi.org\/10.1371\/journal.pmed.1001967\">3<\/a>,<a href=\"https:\/\/doi.org\/10.1093\/infdis\/jiz078\">4<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Di\u011fer Patojenik RNA Vir\u00fcslerine Kar\u015f\u0131 Aktivite<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130nfluenza ve Ebola vir\u00fcslerine kar\u015f\u0131 aktivitesine ek olarak, favipiravirin arenavir\u00fcs, bunyavir\u00fcs, filovir\u00fcs, Bat\u0131 Nil vir\u00fcs\u00fc, sar\u0131 humma vir\u00fcs\u00fc, ayak ve a\u011f\u0131z hastal\u0131\u011f\u0131 vir\u00fcs\u00fcn\u00fcn h\u00fccre k\u00fclt\u00fcr\u00fc ve fare modellerinde terap\u00f6tik etkinli\u011fe sahip oldu\u011fu bulunmu\u015ftur. Viral hemorajik ate\u015fe ve ensefalite neden olan ajanlar\u0131 i\u00e7eren Lassa vir\u00fcs\u00fcne kar\u015f\u0131 da etkilidir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SARS-CoV-2&#8217;deki Rol\u00fc<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Shannon ve ark.12 SARS-CoV-2-RDRp kompleksinin bilinen di\u011fer viral RdRp&#8217;lerden en az 10 kat daha aktif oldu\u011funu bulmu\u015flard\u0131r. Favipiravir, bu viral RdRp enzimini inhibe ederek etki eder ve insan DNA&#8217;s\u0131n\u0131 korurken <strong>favipiravir<\/strong>&#8216;in viral RNA&#8217;ya kolay yerle\u015ftirilmesine izin verir. N\u00fckleozid analoglar\u0131n\u0131n (<strong>favipiravir gibi<\/strong>) COVID-19 tedavisi i\u00e7in umut verici adaylar oldu\u011fu sonucuna varm\u0131\u015flard\u0131r. S\u0131n\u0131rl\u0131 preklinik, in vitro verilerden optimal favipiravir dozunun belirlenmesi g\u00fc\u00e7t\u00fcr. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin, Ebola&#8217;da kullan\u0131lan favipiravirin daha y\u00fcksek dozu, Ebola vir\u00fcs\u00fcn\u00fc (EC50: 67 mM) inhibe etmek i\u00e7in gereken hedef konsantrasyonlar\u0131n influenzadakinden (EC50: 0,48 mM) daha y\u00fcksek oldu\u011funu g\u00f6steren preklinik \u00e7al\u0131\u015fmalara dayanmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">JIKI \u00e7al\u0131\u015fmas\u0131nda 66 hasta \u00fczerinde PK \u00e7al\u0131\u015fmalar\u0131 yap\u0131ld\u0131\u011f\u0131nda tahmin edilen hedef konsantrasyonlara ula\u015f\u0131lamad\u0131. Wang ve ark. SARS-CoV&#8217;yi inhibe etmek i\u00e7in y\u00fcksek favipiravir konsantrasyonlar\u0131n\u0131n (EC50: 61.88uM) gerekli oldu\u011funu bulmu\u015flard\u0131r. Bu nedenle, SARS-CoV-2&#8217;de bu ilac\u0131n mevcut dozunun hangi temele dayand\u0131\u011f\u0131n\u0131 belirlemek zordur. Bu belirsizli\u011fe ra\u011fmen, Hindistan dahil <strong>\u00e7o\u011fu \u00fclkede klinik kullan\u0131mdaki doz, 1. g\u00fcnde 1800 mg, ard\u0131ndan 2-14. G\u00fcnlerde 800 mg&#8217;dir<\/strong>. \u00dclkemizde nas\u0131l ve hangi dozlarda kullan\u0131ld\u0131\u011f\u0131n\u0131 \u00f6\u011frenmek i\u00e7in <a href=\"https:\/\/covid19.saglik.gov.tr\/TR-66301\/covid-19-rehberi.html\">Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 COV\u0130D-19 Tedavi Rehberi<\/a>ne bakabilirsiniz.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">COVID-19&#8217;da Klinik Denemeler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ge\u00e7ti\u011fimiz birka\u00e7 ay i\u00e7inde, COVID-19&#8217;un y\u00f6netiminde <strong>favipiravir<\/strong>&#8216;in etkinli\u011fini de\u011ferlendirmek i\u00e7in t\u00fcm d\u00fcnyada klinik \u00e7al\u0131\u015fmalar yap\u0131lm\u0131\u015ft\u0131r. Ba\u015fl\u0131ca klinik \u00e7al\u0131\u015fmalar burada \u00f6zetlenmi\u015ftir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Favipiravir \u00c7in&#8217;deki Klinik \u00c7al\u0131\u015fmalar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/doi.org\/10.1101\/2020.03.17.20037432\">Chen ve ark.<\/a>, klinik olarak do\u011frulanm\u0131\u015f COVID-19 y\u00f6netiminde iki tedavi kolunu kar\u015f\u0131la\u015ft\u0131rmak i\u00e7in \u00c7in&#8217;de ileriye d\u00f6n\u00fck, a\u00e7\u0131k etiketli \u00e7ok merkezli bir \u00e7al\u0131\u015fma y\u00fcr\u00fctm\u00fc\u015ft\u00fcr (randomizasyondan \u00f6nce semptom ba\u015flang\u0131c\u0131n\u0131n maksimum s\u00fcresi: 12 g\u00fcn). Geleneksel tedavi art\u0131 umifenovir (Arbidol) (g\u00fcnde \u00fc\u00e7 kez 200 mg) veya <strong>favipiravir<\/strong> (<strong>g\u00fcnde iki kez 1600 mg, ard\u0131ndan g\u00fcnde iki kez 600 mg<\/strong>) 7 g\u00fcn boyunca (10 g\u00fcne uzat\u0131labilir). \u00c7al\u0131\u015fma, her iki gruba 1: 1 randomizasyon ile 240 hastadan olu\u015ftu. Yazarlar, <strong>7. g\u00fcnde klinik iyile\u015fme oran\u0131n\u0131n iki grup aras\u0131nda \u00f6nemli \u00f6l\u00e7\u00fcde farkl\u0131l\u0131k g\u00f6stermedi\u011fini bulmu\u015flard\u0131r (favipiravir i\u00e7in% 61.21&#8217;e kar\u015f\u0131l\u0131k umifenovir i\u00e7in% 51.67,% 95 CI: \u22120.0305 ila 0.2213, p = 0.1396). <\/strong>Post hoc analizi,<strong> favipiravir<\/strong> ile tedavi edilen hastalar\u0131n orta derecede COVID-19 (% 71.43&#8217;e kar\u015f\u0131% 55.86,% 95 CI: 0.0271 ila 0.2843, P = 0.0199) ve ate\u015fin daha erken \u00e7\u00f6z\u00fclmesi olanlarda <strong>7. g\u00fcnde klinik iyile\u015fmeye do\u011fru bir e\u011filim g\u00f6sterdi\u011fini g\u00f6stermi\u015ftir<\/strong>. \u00f6ks\u00fcr\u00fck (p &lt;0.0001). Yard\u0131mc\u0131 oksijen tedavisi veya noninvaziv mekanik ventilasyon insidans\u0131 a\u00e7\u0131s\u0131ndan iki grup aras\u0131nda anlaml\u0131 fark yoktu. \u0130ki grup, t\u00fcm nedenlere ba\u011fl\u0131 mortalite, ila\u00e7 ald\u0131ktan sonra nefes darl\u0131\u011f\u0131 ve solunum yetmezli\u011fi a\u00e7\u0131s\u0131ndan benzerdi. T\u00fcm bunlar hafif yan etkiler olarak kabul edildi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fman\u0131n en \u00f6nemli dezavantaj\u0131, <strong>virolojik olarak do\u011frulanm\u0131\u015f vakalardan ziyade klinik olarak do\u011frulanm\u0131\u015f vakalar\u0131n dahil edilmesidir<\/strong>. Bu kohortta, favipiravir grubundaki hastalar\u0131n sadece% 46.55&#8217;i ve umifenovir grubundaki hastalar\u0131n% 38.33&#8217;\u00fc kay\u0131t s\u0131ras\u0131nda n\u00fckleik asit pozitifti. Yazarlar, dahil etme kriterlerinin COVID vakas\u0131n\u0131n tan\u0131mlanmas\u0131 i\u00e7in yayg\u0131n \u00c7in k\u0131lavuzlar\u0131na g\u00f6re tasarland\u0131\u011f\u0131n\u0131 ve o s\u0131rada viral PCR duyarl\u0131l\u0131\u011f\u0131n\u0131n sadece% 30-50 oldu\u011funu belirtmi\u015flerdir. Bir di\u011fer \u00f6nemli dezavantaj, bu ilac\u0131n etkinli\u011fi hakk\u0131nda yeterli bilgi net olmad\u0131\u011f\u0131nda kontrol kolu olarak umifenovir kullanmakt\u0131. \u00d6rnek boyutu, umifenovir kullan\u0131larak klinik iyile\u015fme s\u00fcresinde% 50 azalma oldu\u011fu varsay\u0131larak hesapland\u0131 ve bu hipotezi destekleyen hi\u00e7bir veri yoktu.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">\u00c7in&#8217;deki \u0130kinci \u00c7al\u0131\u015fma<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7in&#8217;den yap\u0131lan <a href=\"https:\/\/doi.org\/10.1016\/j.eng.2020.03.007\">ba\u015fka bir a\u00e7\u0131k etiketli randomize olmayan \u00e7al\u0131\u015fma<\/a> COVID 19 tedavisi. Her iki gruba da nazal soluma yoluyla <strong>interferon-alfa (g\u00fcnde iki kez 5 milyon \u00fcnite)<\/strong> verildi. <strong>16-74 ya\u015flar\u0131 aras\u0131nda<\/strong>, SARS-CoV-2 i\u00e7in pozitif, son 7 g\u00fcn i\u00e7inde semptom ba\u015flang\u0131c\u0131 ve hafif-orta derecede hastal\u0131\u011f\u0131 olanlar dahil edildi. 30 Ocak&#8217;tan 14 \u015eubat&#8217;a kadar, laboratuvarca do\u011frulanm\u0131\u015f COVID 19&#8217;u olan 56 hasta tarand\u0131 ve bunlardan 35&#8217;i <strong>favipiravir<\/strong> i\u00e7in uygunlu\u011fu kar\u015f\u0131lad\u0131. 24 Ocak&#8217;tan 30 Ocak&#8217;a kadar, halihaz\u0131rda <strong>lopinavir \/ ritonavir<\/strong> tedavisi almakta olan 91 laboratuvar onayl\u0131 COVID-19 hastas\u0131, uygunluk a\u00e7\u0131s\u0131ndan tarand\u0131, bunlardan 45&#8217;i kontrol kolu i\u00e7in uygun idi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her iki grubun temel \u00f6zellikleri istatistiksel olarak anlaml\u0131 farkl\u0131l\u0131klar g\u00f6stermedi. <strong>Lopinavir \/ ritonavir<\/strong> grubu ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, bununla birlikte, <strong>favipiravir<\/strong> grubundaki hastalar, <strong>istatistiksel olarak anlaml\u0131 \u015fekilde daha k\u0131sa bir ortalama viral klirens s\u00fcresi (11 g\u00fcne kar\u015f\u0131 4 g\u00fcn, p &lt;0.001)<\/strong>, randomizasyondan 14. g\u00fcnde g\u00f6\u011f\u00fcs BT bulgular\u0131nda iyile\u015fme g\u00f6sterdi ( % 91,4&#8217;e kar\u015f\u0131% 62,2, P = 0,004) ve daha d\u00fc\u015f\u00fck yan etki insidans\u0131 (% 11,43 Vs% 55,56 P de\u011feri &lt;0,001). \u00c7ok de\u011fi\u015fkenli analiz, <strong>favipiravirin ba\u011f\u0131ms\u0131z olarak daha h\u0131zl\u0131 viral klirens ve g\u00f6\u011f\u00fcs BT taramas\u0131 iyile\u015fmesi ile ili\u015fkili oldu\u011funu g\u00f6sterdi.<\/strong> Rastgele olmayan \u00e7al\u0131\u015fman\u0131n s\u0131n\u0131rlamalar\u0131 ve k\u00f6rlemenin olmamas\u0131 nedeniyle, olas\u0131 bir se\u00e7im \u00f6nyarg\u0131s\u0131 sonu\u00e7lar\u0131 kar\u0131\u015ft\u0131rm\u0131\u015f olabilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Favipiravir Japonya&#8217;daki Klinik \u00c7al\u0131\u015fmalar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Japon bir g\u00f6zlemsel \u00e7al\u0131\u015fma grubu, <strong>favipiravir<\/strong>&#8216;in g\u00fcvenli\u011fini ve etkinli\u011fini de\u011ferlendirmek i\u00e7in Japonya&#8217;da hastanede yatan COVID-19 hastalar\u0131n\u0131n ayr\u0131nt\u0131lar\u0131n\u0131 kaydetti.18 \u015eubat-May\u0131s 2020 aras\u0131nda<strong> 407 hastaneden toplam 2158 vaka kaydedildi<\/strong>. Vakalar\u0131n y\u00fczde 90&#8217;\u0131ndan fazlas\u0131nda, <strong>favipiravir 1. g\u00fcnde a\u011f\u0131zdan 1800 mg dozda uygulanm\u0131\u015f<\/strong>, ard\u0131ndan <strong>sonraki g\u00fcnlerde g\u00fcnde iki kez 800 mg uygulanm\u0131\u015ft\u0131r<\/strong>. Medyan tedavi s\u00fcresi 11 g\u00fcnd\u00fc. 7. ve 14. g\u00fcnlerde <strong>klinik iyile\u015fme oranlar\u0131, hafif, orta ve \u015fiddetli hastal\u0131k i\u00e7in s\u0131ras\u0131yla %73.8 ve %87.8, %66.6 ve %84.5 ve %40.1 ve %60.3 idi.<\/strong> Bu nedenle, hafif ve orta derecede hastal\u0131\u011f\u0131 olan hastalar\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011fu hastal\u0131ktan kurtulurken, \u015fiddetli hastal\u0131\u011f\u0131 olanlarda sonu\u00e7lar cesaret verici de\u011fildi. Anket s\u0131ras\u0131nda <strong>\u00f6l\u00fcm oranlar\u0131 hafif, orta ve \u015fiddetli hastal\u0131k i\u00e7in s\u0131ras\u0131yla %5,1, %12,7 ve %31,7 idi<\/strong>. Bu \u00e7al\u0131\u015fman\u0131n, ajan\u0131 almayanlarla klinik seyrin do\u011frudan kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131n\u0131 engelleyen hi\u00e7bir kontrol koluna sahip olmad\u0131\u011f\u0131 vurgulanmal\u0131d\u0131r.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Japon&#8217;daki \u0130kininci \u00c7al\u0131\u015fma<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nafomostat<\/strong> (<strong>daha \u00f6nce MERS-CoV-2 enfeksiyonunda, akut pankreatit ve DIC&#8217;de ba\u015far\u0131yla kullan\u0131lan transmembran proteaz serin 2 inhibit\u00f6r\u00fc<\/strong>) ile <strong>kombinasyon halinde Favipiravir<\/strong>&#8216;in, <strong>Japonya&#8217;da COVID-19&#8217;lu 11 ciddi hastadan olu\u015fan k\u00fc\u00e7\u00fck bir vaka serisinde faydal\u0131 oldu\u011fu bulunmu\u015ftur<\/strong>. Medyan ya\u015f, semptom ba\u015flang\u0131c\u0131ndan yo\u011fun bak\u0131m \u00fcnitesinde yat\u0131\u015fa kadar ge\u00e7en s\u00fcre ve hastaneye yat\u0131\u015fta PaO2 \/ FiO2 oran\u0131 s\u0131ras\u0131yla 68 y\u0131l (IQR 60-69), 8 g\u00fcn (IQR 7-11) ve 131 (IQR 114-198) idi. T\u00fcm hastalar\u0131n oksijen tedavisine, sekiz hastan\u0131n (% 73) invazif mekanik ventilasyona ve 3 hastan\u0131n (% 27) ekstrakorporeal membran oksijenasyonuna (ECMO) ihtiyac\u0131 vard\u0131. <strong>11 hastadan 7&#8217;si mekanik ventilat\u00f6rden ba\u015far\u0131yla ayr\u0131ld\u0131<\/strong>, DNR olan 1 hasta \u00f6ld\u00fc. YB\u00dc ve hastaneden s\u0131ras\u0131yla 9 ve 7 hasta taburcu edildi. Makalenin yay\u0131nland\u0131\u011f\u0131 s\u0131rada bir hasta hala hastanedeydi. Bu kombinasyonla ileriye d\u00f6n\u00fck bir klinik \u00e7al\u0131\u015fman\u0131n (jRCTs031200026) yak\u0131nda Japonya&#8217;da ba\u015flamas\u0131 beklenmektedir(<a href=\"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-020-03078-z\">Kaynak<\/a>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u0130la\u00e7 Etkile\u015fimleri<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Pirazinamid<\/strong>:  favipiravir ile birlikte kullan\u0131m\u0131 \u00fcrik asit d\u00fczeylerini art\u0131r\u0131r. <strong>Bu ila\u00e7lar birlikte kullan\u0131ld\u0131\u011f\u0131nda d\u00fczenli \u00fcrik asit seviyesi takibi zorunludur<\/strong>.<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Repaglinide<\/strong>: <strong>Favipiravir<\/strong>, CYP2C8 yolu yoluyla <strong>repaglinidin metabolizmas\u0131n\u0131 inhibe eder<\/strong>, b\u00f6ylece toksisiteye (<strong>hipoglisemi, ba\u015f a\u011fr\u0131s\u0131, \u00fcst solunum yolu enfeksiyonlar\u0131n\u0131n insidans\u0131n\u0131 art\u0131rma, vb.<\/strong>) Neden olma potansiyelini artt\u0131r\u0131r. <strong>Birlikte dikkatli kullan\u0131m \u00f6nerilir<\/strong>.<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Teofilin<\/strong>,<strong> favipiravir<\/strong>&#8216;in <strong>kandaki d\u00fczeylerini y\u00fckseltir ve favipiravir&#8217;e kar\u015f\u0131 advers reaksiyonlar meydana gelebilir<\/strong>.<\/li><li><strong>Famciclovir, sulindac<\/strong>; Bu ila\u00e7lar\u0131n etkinli\u011fi, <strong>favipiravir ile birlikte uyguland\u0131\u011f\u0131nda azalabilir<\/strong>.<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Asiklovir<\/strong>, favipiravirin aktif k\u0131sma d\u00f6n\u00fc\u015f\u00fcm\u00fcn\u00fc geciktirebilir, b\u00f6ylece antiviral etkinli\u011fini azaltabilir.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Favipiravir Kullan\u0131m\u0131 \u0130le \u0130lgil Ara\u015ft\u0131rmalardan \u00d6\u011frenilenler<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">COVID-19 pandemisinin t\u00fcm d\u00fcnyaya yay\u0131ld\u0131\u011f\u0131 korkutucu h\u0131z, yaln\u0131zca mevcut antiviral ila\u00e7 se\u00e7eneklerimizin ne kadar yetersiz oldu\u011funu ortaya \u00e7\u0131karmaya hizmet etti. <strong>Yeniden ama\u00e7lanan antiviral ila\u00e7lar\u0131n t\u00fcm\u00fc<\/strong>, h\u0131zla y\u00fcr\u00fct\u00fclen klinik deneylerden sonra tedaviyi h\u0131zland\u0131r\u0131lm\u0131\u015ft\u0131r. <strong>Oseltamivir ve ribavirin<\/strong> gibi daha eski, \u00f6nceden var olan <strong>antiviral ila\u00e7lar\u0131n SARS-CoV-2&#8217;ye kar\u015f\u0131 etkili oldu\u011fu g\u00f6sterilememi\u015ftir<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bug\u00fcne kadarki en umut verici antiviral ila\u00e7, ba\u015fka bir amaca uygun hale getirilmi\u015f ila\u00e7 olan remdesevir&#8217;dir<\/strong> ve<strong> iyi y\u00fcr\u00fct\u00fclm\u00fc\u015f bir\u00e7ok \u00e7al\u0131\u015fmada etkili oldu\u011fu g\u00f6sterilmi\u015ftir<\/strong>. Orta derecede \u015fiddetli, ventile edilmemi\u015f hastalarda kullan\u0131ld\u0131\u011f\u0131nda, klinik iyile\u015fme s\u00fcresini iyile\u015ftirdi\u011fi, ve azalm\u0131\u015f mortaliteye do\u011fru bir e\u011filim sa\u011flad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir, ancak <strong>\u00f6nemli bir mortalite yarar\u0131 g\u00f6sterilmemi\u015ftir<\/strong>. <strong>Bu ilac\u0131n etkisi en iyi ihtimalle m\u00fctevaz\u0131 g\u00f6r\u00fcnmektedir ve COVID-19 y\u00f6netimindeki yerini de\u011ferlendirmek i\u00e7in acilen daha b\u00fcy\u00fck \u00f6l\u00e7ekli \u00e7al\u0131\u015fmalara ihtiya\u00e7 vard\u0131r<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Remdesivir<\/strong> ile benzer bir etki mekanizmas\u0131na sahip olan ancak oral yoldan uygulanan bir ila\u00e7 olan <strong>Favipiravir<\/strong>, <strong>kullan\u0131m\u0131n\u0131 desteklemek i\u00e7in daha az g\u00fc\u00e7l\u00fc destekleyici verilere sahiptir<\/strong>, ancak yine de <strong>hafif ila orta vakalarda dikkate al\u0131nmaya de\u011fer bir ajan olarak ortaya \u00e7\u0131kmaktad\u0131r<\/strong>. Bu ila\u00e7la yap\u0131lan ilk Hindistan \u00e7al\u0131\u015fmas\u0131n\u0131n \u00f6n sonu\u00e7lar\u0131, klinik iyile\u015fme s\u00fcresinde k\u00fc\u00e7\u00fck ama \u00f6nemli bir iyile\u015fme ve <strong>iki g\u00fcn daha k\u0131sa bir viral yay\u0131lma s\u00fcresi ile cesaret vericidir<\/strong>. Perspektif olarak ifade edilirse, influenzada 20 oseltamivir \u00e7al\u0131\u015fmas\u0131n\u0131n Cochrane incelemesi, yayg\u0131n olarak kullan\u0131lan bu ilac\u0131n semptomlar\u0131n klinik olarak hafifletilmesine kadar ge\u00e7en s\u00fcreyi yaln\u0131zca 16,8 saat k\u0131saltt\u0131\u011f\u0131n\u0131 <a href=\"https:\/\/doi.org\/10.3310\/hta20420\">g\u00f6stermi\u015ftir<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Favipiravir&#8217;in Avantajlar\u0131<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Favipiravirin temel avantajlar\u0131, oral yoldan uygulanmas\u0131 ve semptomatik olan ancak hastaneye yat\u0131r\u0131lacak kadar hasta olmayan hastalarda verilebilmesidir. COVID-19 hastalar\u0131n\u0131n \u00e7o\u011fu (% 85) hafif ila orta \u015fiddette hastal\u0131\u011fa sahip oldu\u011fundan ve evde tedavi edilebildi\u011finden, bu ila\u00e7 potansiyel olarak \u00e7ok say\u0131da hastada kullan\u0131labilir. Herhangi bir antiviralde oldu\u011fu gibi, viremiyi azaltmada etkili olabilmesi i\u00e7in favipiravirin semptomlar\u0131n ba\u015flang\u0131c\u0131ndan sonra erken uygulanmas\u0131 gerekti\u011fi vurgulanmal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;Viral bula\u015fma s\u00fcresini potansiyel olarak k\u0131saltmadaki rol\u00fc, evde ve toplumda viral bula\u015fmay\u0131 azaltabilece\u011finden epidemiyolojik bir etkiye sahip olabilir. Favipiravirin, maruz kalan ancak sa\u011fl\u0131kl\u0131 temaslarda profilaksideki rol\u00fc de devam eden bir ara\u015ft\u0131rmada incelenmektedir.31 Favipiravir, bu ila\u00e7lar\u0131n tamamlay\u0131c\u0131 veya sinerjik bir \u015fekilde etki edip etmedi\u011fini g\u00f6rmek i\u00e7in umifenovir gibi di\u011fer antiviral ila\u00e7larla kombinasyon halinde de de\u011ferlendirilmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kaynak: <a href=\"https:\/\/www.clinicaltrialsarena.com\/news\/glenmark-favipiravir-combo-trial\/\">Glenmark Starts Phase III Favipiravir Combination Trial for Covid-19<\/a> ve <a href=\"https:\/\/www.pharmaceutical-business-review.com\/news\/appili-therapeutics-favipiravir-canada-trial\/\">Appili Set to Evaluate Favipiravir as Preventive Measure against Covid-19,&nbsp;Pharmaceutical Business review&nbsp;(2020)[cited 24 July 2020].<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Favipiravir Yan Etkileri \u0130le \u0130lgili Sonu\u00e7lar<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Favipiravir yan etkileri, <strong>asemptomatik hiper\u00fcrisemi<\/strong> ve en s\u0131k bildirilen yan etkiler olan <strong>transaminazlarda hafif, geri d\u00f6n\u00fc\u015f\u00fcml\u00fc y\u00fckselme ile de kabul edilebilir g\u00f6r\u00fcnmektedir<\/strong>. Hindistan vakalar\u0131nda \u00f6zel bir risk ortaya \u00e7\u0131kmad\u0131. Ancak <strong>teratojeniktir ve asla hamile kad\u0131nlarda kullan\u0131lmamal\u0131d\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Favipiravir as\u0131l dezavantaj\u0131 olarak, ilk g\u00fcn 18 tablet ve ard\u0131ndan tedavinin geri kalan\u0131nda g\u00fcnde 8 tabletlik bir y\u00fckleme dozuna ula\u015fan y\u00fcksek bir hap y\u00fck\u00fcd\u00fcr<\/strong>. Son zamanlarda \u00fcreticilerden biriyle <strong>400 mg dozun piyasaya s\u00fcr\u00fclmesiyle, y\u00fcksek hap y\u00fck\u00fc ile ilgili bu endi\u015feler k\u0131smen azalacakt\u0131r<\/strong>. <strong>2 haftay\u0131 bulan \u00f6nerilen tedavi s\u00fcresi de bir dezavantaj olabilir.<\/strong> Burada yine \u00fcreticiler, hasta o zamana kadar tamamen iyile\u015fmi\u015fse ilac\u0131n bir hafta i\u00e7inde kesilebilece\u011fini belirtiyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u00fcm bu bilgilerin \u0131\u015f\u0131\u011f\u0131nda, sonu\u00e7 olarak, <strong>favipiravir hafif ila orta derecede semptomatik SARS-CoV-2 ile enfekte vakalar\u0131n tedavisinde de\u011ferli bir ila\u00e7 olarak ortaya \u00e7\u0131km\u0131\u015ft\u0131r<\/strong>. Ayr\u0131ca, bu ilac\u0131n kay\u0131ts\u0131z \u015farts\u0131z \u00f6nerilebilmesi i\u00e7in daha b\u00fcy\u00fck RK\u00c7&#8217;lere acilen ihtiya\u00e7 vard\u0131r. Bu makalenin b\u00fcy\u00fck b\u00f6l\u00fcm\u00fc <a href=\"https:\/\/doi.org\/10.1016\/j.mjafi.2020.08.004\">Favipiravir: A new and emerging antiviral option in COVID-19<\/a> adl\u0131 makaleden \u00e7eviri derlemedir.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u015euan d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndan bildirilen 16 milyondan fazla vaka  [&#8230;]<\/p>\n","protected":false},"author":1,"featured_media":7137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[217,222,224,97,133,141,135,145,104,111,92,131,136,132,218,143,106,9,225,134,142,144,219],"class_list":["post-7124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-molekul","tag-antiviral","tag-asi","tag-asi-uretimi","tag-bilgisayar-destekli-ilac-tasarimi","tag-covid","tag-covid-ilac","tag-covid19","tag-covid19-tedavi","tag-enzim-inhibisyonu","tag-enzim-inhibitoru","tag-enzimler","tag-favicovir","tag-favicovir-yan-etkileri","tag-favipiravir","tag-favipiravir-yan-etkileri","tag-ilac-gelistirme","tag-ilac-kesfi","tag-ilac-tasarimi","tag-influenza","tag-koronavirus","tag-koronavirus-ilac","tag-rna-polimeraz","tag-yan-etki"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/7124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7124"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/7124\/revisions"}],"predecessor-version":[{"id":9454,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/7124\/revisions\/9454"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/media\/7137"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}